

January 26, 2023



IceCure's ProSense Featured in Breast Session at the Society of Interventional Oncology's Annual Scientific Meeting in Washington, D.C.

- ***Panel discussion included doctors currently using the ProSense cryoablation system***
- ***Live ProSense demonstrations conducted at IceCure's booth***

CAESAREA, Israel, Jan. 26, 2023 /PRNewswire/ -- [IceCure Medical Ltd.](#) (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced its participation in the Society of Interventional Oncology's Annual Scientific Meeting ("[SIO2023](#)") in Washington, D.C. on January 19 - 23, 2023. ProSense was demonstrated throughout the duration of the conference at IceCure's booth. Separately, in a breast session organized by SIO2023, ProSense was featured in a panel discussion on January 21st led by Dr. Kenneth Tomkovich and included Dr. Robert Ward, both ProSense users. The discussion included cryoablation as a treatment option as well as a mention of ICE3 interim trial results.



Dr. Tomkovich, Diagnostic and Interventional Radiologist with Princeton Radiology and Director of Breast Imaging and Interventions at CentraState Medical Center, is Co-lead Investigator of IceCure's landmark ICE3 study for the treatment of small, low-risk, early-stage malignant breast tumors. Dr. Ward, Assistant Professor of Diagnostic Imaging at the Warren Alpert Medical School of Brown University, Program Director for the Breast Imaging

Fellowship, Associate Chief of Diagnostic Imaging at Women & Infants Hospital, specializes in women's imaging and breast tumor cryoablation.

Commenting on the growing interest in ProSense, Dr. Tomkovich stated, "we are seeing increasing interest from interventional radiologists and interventional oncologists, many of whom are practitioners who previously were not treating breast cancer patients. Their interest appears to be driven by the encouraging ICE3 interim results, which can drive the development of new patient markets for practitioners while making the minimally invasive procedure more accessible to patients." **About IceCure Medical Ltd.**

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared to-date by the U.S. Food and Drug Administration and approved in European with the CE Mark.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws and Israeli securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statement in this press release when it discusses: the increasing interest in its products amongst practitioners and the potential for its products to drive development of new patient markets while making minimally invasive procedures more accessible to patients. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (the "SEC") on April 1, 2022, as amended, which is available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. The Company is not responsible for the contents of third-party websites.

IR Contact:

Ronen Tsimmerman

ronent@icecure-medical.com

Logo - https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg

View original content: <https://www.prnewswire.com/news-releases/icecures-prosense-featured-in-breast-session-at-the-society-of-interventional-oncologys-annual-scientific->

meeting-in-washington-dc-301731482.html

SOURCE IceCure Medical